Riskpilot← Back to searchSign inGet full accessRoxtaPharma AB
ABBankruptOrg 5591684583Manufacture of pharmaceutical preparations · NACE 2120Est. 20180 employees
Revenue 2023
—
EBITDA margin
—
Equity ratio
—
Financial strength
Net profit 2023
—
0 employees
| Revenue | — | — |
| EBITDA | SEK 0 | — |
| Net profit | — | — |
| Total assets | — | — |
| Equity | — | — |
| Employees | 0 | — |
Legal name
RoxtaPharma AB
Org number
5591684583
Legal form
Aktiebolag
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
20 augusti 2018
Share capital
SEK 50 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2023-12-31
Financial year
January – December
Signatory rights
Firman tecknas ensam av likvidatorn
Company purpose
Bolaget ska bedriva växtodling och försäljning av dessa produkter. Huvudsaklig produktionsinriktning är, växtodling (livsmedelsproduktion, t.ex. (tomat, gurka, bär, frukt) inom växthus med användning av Hydroponisk och Aeroponisk metoder. Det innebär en jordlös odling metod där man använda näringslösämne istället av jord. Sekundär produktionsinriktning är, Krydda- och Medicinalväxter, växt som används för framställning av läkemedel eller har läkemedelseffekter.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | — | — |
| Staff expenses | — | — | — | — | — |
| EBITDA | — | — | — | 0 | 0 |
| Depreciation & amort. | −0 | −0 | −0 | — | — |
| EBIT | 0 | 0 | 0 | 0 | 0 |
| Net financials | — | — | — | — | — |
| Profit before tax | 0 | 0 | 0 | 0 | 0 |
| Tax | −0 | −0 | −0 | — | — |
| Net profit | 0 | 0 | 0 | — | — |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Total assets | 50 | 50 | 50 | — | — |
| Equity | 50 | 50 | 50 | — | — |
| Long-term debt | 0 | 0 | 0 | — | — |
| Short-term debt | 0 | 0 | 0 | — | — |
| Total debt | — | — | — | — | — |
EBITDA margin
0.0%
This company
15.8%
Market median
-100% vs market
20192023
Equity ratio
0.0%
This company
38.2%
Market median
-100% vs market
20192023
Return on equity
0.0%
This company
18.4%
Market median
-100% vs market
20192023
Net profit margin
0.0%
This company
8.1%
Market median
-100% vs market
20192023
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20192023
Debt / equity
-1.00×
This company
0.62×
Market median
+261% vs market
20192023
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2018-08-01 – 2019-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
LM Liquidator | Liquidator | 2024 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2022 | — | — | |
| Chairman | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of RoxtaPharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lars Mikael Söderman | Liquidator | 0 companies |
| Parivash Saraji | Board of Directors | 0 companies |
| Mona Vahidi Wennergren | Board of Directors | 0 companies |
| Ataollah Nazifishirayi | Chairman | 0 companies |
| Mansoore Roxan Nazifishirayi | Chairman | 0 companies |